Benazeprilat

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Benazeprilat 是一种具有口服活性的贝那普利活性代谢物，贝那普利是一种具有抗高血压活性的含羧基血管紧张素转换酶 ACE 抑制剂。Benazeprilat 是一种公认的抗高血压剂，无论是单药研究还是与其他类别的药物（包括噻嗪类利尿剂和钙通道阻滞剂）联合使用。Benazeprilat 是减少与心血管风险和继发性终末器官损伤相关的各种病理的一线研究药物。

Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage.

——

Benazeprilat (10 mg/kg, intravenous injection) and amlodipine (0.5 mg/kg, intravenous injection) in combination produce great hypotensive effect.Benazepril (0.7 mg/kg, oral) markedly influences the dynamics of systemic RAAS peptides, resulting in a substantial decrease in AII and ALD while increasing PRA and AI.Animal Model:Male SHR (14-16 weeks of age, 250-350 g).Dosage:10 mg/kg Administration:I.V; once a day for 2 days.Result:Produced hypotensive effect.Animal Model:Beagle dogs (12.0-19.5 kg).Dosage:0.7 mg/kg Administration:P.O, once a day for 5 days.Result:Effected systemic RAAS peptides.

——

Endocrinology/Hormones

RAAS

RAAS | Endogenous Metabolite

——

——

86541-78-8

396.44

C22H24N2O5

>98% (HPLC)

——

C(C(O)=O)N1C=2C(CC[C@H](N[C@@H](CCC3=CC=CC=C3)C(O)=O)C1=O)=CC=CC2

——

(-20℃)

With Ice Pack

≥ 2 years